The appointment marks a strategic transition for the Goleta-based company as it pivots from a research-heavy entity into a full-scale commercial diagnostics player. Wang, who previously served as President and Chief Technology Officer, has been instrumental in the development of the company’s Metrix molecular diagnostic platform. His work has spanned the full lifecycle of the business, including large-scale manufacturing and internal culture development.

Ferguson noted that the shared leadership structure reflects the reality of how the pair has managed operations for over a decade. By formalizing the arrangement, the company aims to sharpen its focus on scaling the Metrix platform, which currently provides FDA-authorized molecular testing for COVID-19 and influenza. As the firm looks to diversify its test menu and reach a broader customer base, the co-CEO model is intended to provide the organizational clarity required to balance ongoing technical innovation with aggressive commercial expansion.